Does photobiomodulation reduce the risk of severe oral mucositis in head and neck cancer?
Oral mucositis is a painful inflammation and ulceration of the mouth lining that commonly occurs during radiation or chemoradiation for head and neck cancer. Severe mucositis (grade 3 or higher) can make eating, drinking, and speaking extremely difficult, often requiring treatment breaks. Photobiomodulation (PBM), also called low-level laser therapy, uses specific wavelengths of light to reduce inflammation and promote healing. Multiple studies show that PBM can meaningfully lower the chance of developing severe oral mucositis in head and neck cancer patients.
What the research says
A 2025 meta-analysis of 30 randomized controlled trials involving 1,748 head and neck cancer patients found that photobiomodulation reduced the risk of severe oral mucositis by 54% (RR 0.46, 95% CI: 0.29-0.71, P < 0.001) compared to control groups 5. The same analysis also showed a 65% reduction in severe oral pain (RR 0.35, 95% CI: 0.23-0.53) 5. These benefits were consistent across different PBM protocols, including various laser wavelengths and application sites 5.
A separate 2026 meta-analysis of 7 randomized trials (329 patients) that included various cancer types also found PBM highly effective for managing oral mucositis overall (RR 0.50, 95% CI: 0.35-0.73) 2. This analysis noted that laser wavelengths commonly ranged from 635 to 980 nm, with 660 nm being most frequent for intraoral application 2.
An observational study of 118 head and neck cancer patients receiving daily prophylactic PBM during radiotherapy reported that severe mucositis (grade 3/4) occurred in 28% of patients 7. While this study lacked a control group, it suggests that even with PBM, some patients still develop severe mucositis, particularly those with additional risk factors like concurrent chemoradiation or poor nutritional status 7.
Evidence in children is less definitive. A systematic review of low-level laser therapy in children with cancer found that PBM may reduce mucositis severity and pain, but the authors noted that more trials are needed due to variation in protocols and risk of bias from insufficient blinding 6.
What to ask your doctor
- Is photobiomodulation available at your treatment center, and would it be appropriate for my specific cancer treatment plan?
- How often and at what point during my radiation or chemoradiation should PBM sessions be scheduled for best prevention?
- Are there any additional risk factors, such as concurrent chemotherapy or nutritional concerns, that might increase my chance of severe mucositis even with PBM?
- What other preventive measures, like oral care protocols or medications, should I combine with PBM to further reduce my risk?
This question is drawn from common patient questions about Oncology and answered using cited medical research. We do not provide individualized advice.